Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Another view of active-controlled trials.

A L Gould1

  • 1Merck, Sharp, and Dohme Research Laboratories, West Point, Pennsylvania 19486.

Controlled Clinical Trials
|August 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Strain-level diversity of symbiont communities between individuals and populations of a bioluminescent fish.

The ISME journal·2023
Same author

Chromosome-Level Genome Assembly of the Bioluminescent Cardinalfish Siphamia tubifer: An Emerging Model for Symbiosis Research.

Genome biology and evolution·2022
Same author

Life history of the symbiotically luminous cardinalfish Siphamia tubifer (Perciformes: Apogonidae).

Journal of fish biology·2016
Same author

Segregation effects on the properties of (AuAg)₁₄₇.

Physical chemistry chemical physics : PCCP·2014
Same author

Symbiosis initiation in the bacterially luminous sea urchin cardinalfish Siphamia versicolor.

Journal of fish biology·2012
Same author

Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone.

Diabetes, obesity & metabolism·2009
Same journal

On the generation and ownership of alpha in medical studies.

Controlled clinical trials·2004
Same journal

An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia.

Controlled clinical trials·2004
Same journal

Symptom recording in a randomised clinical trial: paper diaries vs. electronic or telephone data capture.

Controlled clinical trials·2004
Same journal

Statistical comparison of random allocation methods in cancer clinical trials.

Controlled clinical trials·2004
Same journal

Analyzing bronchodilation with emphasis on disease type, age and sex.

Controlled clinical trials·2004
Same journal

Geographic variability in patient characteristics, treatment and outcome in an International Trial of Magnesium in acute myocardial infarction.

Controlled clinical trials·2004
See all related articles

This study presents a new method for analyzing active-controlled trials by incorporating historical placebo data. This approach enhances the interpretation of treatment efficacy when placebos are ethically challenging.

Area of Science:

  • Clinical Trials Methodology
  • Pharmacoeconomics
  • Biostatistics

Background:

  • Placebo-controlled trials face ethical challenges with rising availability of effective therapies.
  • Active-controlled trials for efficacy can have interpretational issues and do not always promote best practices.

Purpose of the Study:

  • To describe an alternative analysis for active-controlled trials using historical placebo data.
  • To leverage existing data on placebo and active agent responses to assess treatment differences.
  • To improve the interpretation of efficacy in trials where placebo use is limited.

Main Methods:

  • Utilizes historical data from prior placebo-controlled trials.
  • Incorporates information on both placebo and active agent responses.

Related Experiment Videos

  • Applies this to active-controlled trials or those with minimal placebo groups.
  • Assesses the likelihood of a significant active-placebo difference.

    • Main Results:

    • The proposed method uses prior trial data to inform current active-controlled trial analysis.
    • Sensitivity of treatment comparisons is directly linked to trial design and execution quality.
    • Illustrates the method with H2-receptor antagonist trials for duodenal ulcer.

    Conclusions:

    • This approach offers a viable alternative for efficacy trials when traditional placebo controls are problematic.
    • It enhances the interpretability of active-controlled trials by integrating historical evidence.
    • Emphasizes the importance of robust trial design and execution for reliable results.